Skip to Main Content

Paper Details

Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia.
Cancer Discov
4
2022
5'-nucleotidase cytosolic II, 5'-nucleotidase cytosolic II (NT5C2) gene, 6-MP, 6-mercaptopurine, ALL, Acute Lymphoblastic Leukemia, CRCD2, NT5C2, NT5C2 mutations, NT5C2 nucleotidase, NT5C2 wild-type leukemias, Ser502, acute lymphoblastic leukemia, leukemias, thiopurine
Author NameAffiliation
Julie M Gastier-FosterBaylor College of Medicine
Julie M Gastier-Foster
Julie M Gastier-FosterBaylor College of Medicine
Julie M Gastier-Foster
Mignon L LohSeattle Children's Hospital, University of Washington
Liang TongColumbia University
Brent R StockwellColumbia University
Brent R StockwellColumbia University
  • 1 - 8

Datasets

Release 1.2